Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics. Royalty Pharma plc (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Subject Matter, and Seyfarth Shaw advised Kivvit. Subject Matter, a portfolio company of Coral Tree Partners, announced its acquisition of Kivvit to create...
You must be a Standard 1 Year member to access this content.
Goodwin Procter acted as counsel to FibroGen, and Gibson Dunn acted as counsel to Morgan Stanley Tactical Value. FibroGen, Inc. (NASDAQ: FGEN) announced a non-dilutive term...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised FibroGen, Inc. on the deal. FibroGen, Inc. announced its capped royalty monetization financing with NovaQuest Capital Management. The non-dilutive financing provides FibroGen with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised CharterUP on the deal. CharterUP announced the completion of its $60 million in Series A. The financing round was led by Tritium Partners. CharterUP...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised TA Associates on the deal. TA Associates announced its strategic growth investment in Veracode, taking a majority equity position in the business. Veracode is...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised 2U, Inc. on the deal while Goodwin Procter represented edX. 2U, Inc., a global leader in education technology, announced a definitive agreement to acquire...
You must be a Standard 1 Year member to access this content.
